JASPER THERAPEUTICS, INC. Increase (Decrease) in Other Accrued Liabilities
JASPER THERAPEUTICS, INC. (JSPR) reported Increase (Decrease) in Other Accrued Liabilities of -$911.00 thousand for the 6-month period ending 2022-06-30, per its 10-Q filed 2022-08-12.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherAccruedLiabilities · last filed 2022-08-12
- JASPER THERAPEUTICS, INC. increase (decrease) in other accrued liabilities for the quarter ending 2022-06-30 was -$1.30M, a 191.34% decline year-over-year.
- JASPER THERAPEUTICS, INC. increase (decrease) in other accrued liabilities for the quarter ending 2022-03-31 was $386.00K.
- JASPER THERAPEUTICS, INC. increase (decrease) in other accrued liabilities for the quarter ending 2021-12-31 was -$2.11M, a 267.83% decline year-over-year.
- JASPER THERAPEUTICS, INC. increase (decrease) in other accrued liabilities for the quarter ending 2021-09-30 was $1.94M.
- JASPER THERAPEUTICS, INC. increase (decrease) in other accrued liabilities for fiscal 2021 was $959.00K, a 21.71% decline from fiscal 2020.
- JASPER THERAPEUTICS, INC. increase (decrease) in other accrued liabilities for fiscal 2020 was $1.23M.
| Period end | Increase (Decrease) in Other Accrued Liabilities 3 month | Increase (Decrease) in Other Accrued Liabilities 6 month | Increase (Decrease) in Other Accrued Liabilities 9 month | Increase (Decrease) in Other Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2022-06-30 | -$1.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | -$911.00K 10-Q · filed 2022-08-12 | -$3.02M derived: sum of 3 quarters · filed 2022-08-12 | -$1.09M derived: sum of 4 quarters · filed 2022-08-12 |
| 2022-03-31 | $386.00K 10-Q · filed 2022-05-12 | -$1.73M derived: sum of 2 quarters · filed 2022-05-12 | $211.00K derived: sum of 3 quarters · filed 2022-05-12 | $1.63M derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-12-31 | -$2.11M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | -$175.00K derived: sum of 2 quarters · filed 2022-03-18 | $1.25M derived: sum of 3 quarters · filed 2022-08-12 | $959.00K 10-K · filed 2022-03-18 |
| 2021-09-30 | $1.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $3.36M derived: sum of 2 quarters · filed 2022-08-12 | $3.07M 10-Q · filed 2021-11-12 | $4.33M derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-06-30 | $1.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $1.13M 10-Q · filed 2022-08-12 | $2.39M derived: sum of 3 quarters · filed 2022-08-12 | |
| 2021-03-31 | -$286.00K 10-Q · filed 2022-05-12 | $973.00K derived: sum of 2 quarters · filed 2022-05-12 | ||
| 2020-12-31 | $1.26M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | $1.23M 10-K · filed 2022-03-18 | ||
| 2020-09-30 | -$34.00K 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |